Birch Allergy Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | ALK-Abello A/S, Allergy Therapeutics Plc., Regeneron Pharmaceuticals, Desentum, HAL Allergy Group

The Key Birch Allergy Companies in the market include - ALK-Abello A/S, Allergy Therapeutics Plc., Regeneron Pharmaceuticals Inc., Desentum., HAL Allergy Group., Roxall Medizin GmbH., Worg Pharmaceuticals AG., S-TARget therapeutics GmbH., Adamis Pharmaceuticals Crp., and others .

DelveInsight's "Birch Allergy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Birch Allergy, historical and forecasted epidemiology as well as the Birch Allergy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Birch Allergy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Birch Allergy Market Forecast [https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Birch Allergy Market Report:

*
The Birch Allergy market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In September 2025, Regeneron Pharmaceuticals' first-in-class investigational allergen-blocking monoclonal antibodies (mAbs) achieved their primary endpoints in two Phase III trials involving adults with moderate-to-severe cat or birch allergies. In the cat allergen study, participants received a single dose of REGN1908 and REGN1909 or a placebo. One week after treatment with the FelD1-blocking antibodies, the primary endpoint of ocular itch and key secondary endpoints-conjunctival redness and skin prick reactivity-were successfully met, showing reductions of 52% in itch, 39% in conjunctival redness, and 44% in skin prick reactivity.

*
In April 2025, Desentum Oy, a clinical-stage biopharmaceutical firm focused on innovative immunotherapies for allergies, reported positive clinical results for its birch pollen allergy vaccine, DM-101PX. The short-course treatment was shown to be safe, well tolerated, and capable of eliciting a robust and sustained allergen-specific IgG4 response in patients with birch pollen allergies. Immunoglobulins induced by DM-101PX effectively inhibited IgE-mediated basophil activation, supporting the vaccine's potential to trigger a protective immune response.

*
The pooled prevalence figures, according to the French business DJO Global, show that 35% of people over 65 and 23% of adults aged 18 to 65 in France suffer with Birch Allergy

*
According to a study by "Forkel et al. (2020), the prevalence of sensitization to one or more aeroallergens was estimated to be 33.6% of the general population in Germany based on the "German Health Interview and Examination Survey for Adults" (DEGS1) from 2008 to 2011

*
The most prevalent seasonal allergy is birch pollen allergy. Between 8 and 16% of people are allergic-sensitized. There are seven different forms of birch pollen allergens, but Bet v 1 specific IgE is the most common one

*
Key Birch Allergy Companies: ALK-Abello A/S, Allergy Therapeutics Plc., Regeneron Pharmaceuticals Inc., Desentum., HAL Allergy Group., Roxall Medizin GmbH., Worg Pharmaceuticals AG., S-TARget therapeutics GmbH., Adamis Pharmaceuticals Crp., and others

*
Key Birch Allergy Therapies: REGN5713-5714-571, SQ tree SLIT-tablet, ILT-101, sublingual immunotherapy, AllerT, and others

*
The Birch Allergy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Birch Allergy pipeline products will significantly revolutionize the Birch Allergy market dynamics.

Get a Free sample for the Birch Allergy Market Report:

https://www.delveinsight.com/report-store/birch-allergy-market [https://www.delveinsight.com/report-store/birch-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Birch Allergy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Birch Allergy Epidemiology Segmentation:

The Birch Allergy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Birch Allergy

*
Prevalent Cases of Birch Allergy by severity

*
Gender-specific Prevalence of Birch Allergy

*
Diagnosed Cases of Episodic and Chronic Birch Allergy

Download the report to understand which factors are driving Birch Allergy epidemiology trends @ Birch Allergy Epidemiology Forecast [https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Birch Allergy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Birch Allergy market or expected to get launched during the study period. The analysis covers Birch Allergy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Birch Allergy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Birch Allergy Therapies and Key Companies

*
REGN5713-5714-5715: Regeneron Pharmaceuticals

*
SQ tree SLIT-tablet: ALK-Abello A/S

*
ILT-101: Assistance Publique

*
sublingual immunotherapy: HAL Allergy

*
AllerT: Anergis

Discover more about therapies set to grab major Birch Allergy market share @ Birch Allergy Treatment Market [https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Birch Allergy Market Drivers

*
Increasing prevalence of Birch Allergy

*
Ongoing development of precision medicine

*
Expansion of health care system

Birch Allergy Market Barriers

*
Ineffectiveness/Failure of Treatment

*
Slow uptake of immunotherapy

Scope of the Birch Allergy Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Birch Allergy Companies: ALK-Abello A/S, Allergy Therapeutics Plc., Regeneron Pharmaceuticals Inc., Desentum., HAL Allergy Group., Roxall Medizin GmbH., Worg Pharmaceuticals AG., S-TARget therapeutics GmbH., Adamis Pharmaceuticals Crp., and others

*
Key Birch Allergy Therapies: REGN5713-5714-571, SQ tree SLIT-tablet, ILT-101, sublingual immunotherapy, AllerT, and others

*
Birch Allergy Therapeutic Assessment: Birch Allergy current marketed and Birch Allergy emerging therapies

*
Birch Allergy Market Dynamics: Birch Allergy market drivers and Birch Allergy market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Birch Allergy Unmet Needs, KOL's views, Analyst's views, Birch Allergy Market Access and Reimbursement

To know more about Birch Allergy companies working in the treatment market, visit @ Birch Allergy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Birch Allergy Market Report Introduction

2. Executive Summary for Birch Allergy

3. SWOT analysis of Birch Allergy

4. Birch Allergy Patient Share (%) Overview at a Glance

5. Birch Allergy Market Overview at a Glance

6. Birch Allergy Disease Background and Overview

7. Birch Allergy Epidemiology and Patient Population

8. Country-Specific Patient Population of Birch Allergy

9. Birch Allergy Current Treatment and Medical Practices

10. Birch Allergy Unmet Needs

11. Birch Allergy Emerging Therapies

12. Birch Allergy Market Outlook

13. Country-Wise Birch Allergy Market Analysis (2020-2034)

14. Birch Allergy Market Access and Reimbursement of Therapies

15. Birch Allergy Market Drivers

16. Birch Allergy Market Barriers

17. Birch Allergy Appendix

18. Birch Allergy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=birch-allergy-market-trends-point-to-steady-growth-ahead-by-2034-delveinsight-analysis-reveals-alkabell-as-allergy-therapeutics-plc-regeneron-pharmaceuticals-desentum-hal-allergy-group]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.